MEI Pharma报告季度亏损、股票下跌, 但从StockNews. com得到“买入”评级。 MEI Pharma reports quarterly loss, stock dips, but receives a "buy" rating from StockNews.com.

MEI Pharma是一家发展癌症治疗的临床级制药公司,报告每季度每股损失0.48美元,导致其股票价格下降0.04美元至2.66美元。 MEI Pharma, a clinical-stage pharmaceutical company developing cancer treatments, reported a quarterly loss of $0.48 per share, causing its stock price to drop by $0.04 to $2.66. 尽管损失惨重, StockNews. com最近以“购买”的评级开始报导。 Despite the loss, StockNews.com recently initiated coverage with a "buy" rating. 该公司的市场上限为1 772万美元,并正在为各种癌症开发Zandelisib和Voruciclib等药物。 The company has a market cap of $17.72 million and is developing drugs like Zandelisib and Voruciclib for various cancers.